Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 11 for:    mistletoe clinical trial
Previous Study | Return to List | Next Study

Trial of Mistletoe Extract in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03051477
Recruitment Status : Active, not recruiting
First Posted : February 13, 2017
Last Update Posted : February 24, 2022
Believe Big
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:
This study will seek to determine the safety and toxicity profile as well as the maximum tolerated dose of Helixor® M in patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: Helixor® M Phase 1

Detailed Description:
This study is a Phase I study that consists of two phases: a dose escalation phase and an expansion phase. The dose escalation phase will be used to evaluate the safety and toxicity of Helixor® M (mistletoe extract). An accelerated titration design (ATD) will be utilized to determine the MTD. The expansion phase will be used to obtain preliminary efficacy data about Helixor® M.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalating Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
Actual Study Start Date : March 1, 2017
Actual Primary Completion Date : January 29, 2021
Estimated Study Completion Date : August 2022

Arm Intervention/treatment
Experimental: Helixor® M
Advanced solid tumors
Drug: Helixor® M
3-hour IV infusion on Monday, Wednesday, and Friday of each week.
Other Name: Mistletoe extract

Primary Outcome Measures :
  1. Number of participants experiencing toxicities [ Time Frame: 3 years ]
    Number of participants who experience side effects

  2. Maximum tolerated dose (MTD) [ Time Frame: 2 years ]
    The highest dose that does not cause unacceptable side effects

Secondary Outcome Measures :
  1. Tumor marker kinetics [ Time Frame: 3 years ]
    Changes in disease specific bio markers: analyzed as percent change and presented in a waterfall plot of response.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Any patients who have had any prior treatment with Mistletoe (injection or infusion) will not be eligible for this study.

Inclusion Criteria

  • Patients with advanced solid tumors and have received first line standard systemic therapy with chemotherapy, immunotherapy, hormonal therapy or other standard treatments for metastatic disease. Patients must either have progressed, are refractory, have stable disease and/or removed from therapy due to toxicities. Patients beyond first line therapy that do not meet criteria may be considered on a case by case basis and allowed at discretion of PI.
  • Patients with the presence of at least one measurable lesion as defined by RECIST 1.1 criteria for response assessment. Prostate cancer patients with bone disease only are eligible.
  • Age >18 years.
  • ECOG performance status 0-2
  • Life expectancy of greater than 3 months.
  • Patients must have normal organ and marrow function as defined below (without growth factor or transfusion support within 14 days prior to first dose of investigational product):

    • WBC ≥ 3,000/mcL
    • Absolute neutrophil count ≥ 1,000/mcL
    • Platelets ≥ 90,000/mcL
    • Hemoglobin ≥ 9.0 g/dL
    • Total bilirubin ≤ 1.5 X ULN (patients with diagnosed Gilbert's Syndrome will not be excluded if their direct bilirubin is within normal institutional limits)
    • AST(SGOT)/ALT(SGPT) ≤ 2.5 X ULN
    • Creatinine ≤1.5 x ULN OR creatinine clearance ≥ 50 mL/min/1.73 m2
  • Female patient of childbearing potential has a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the patient to be eligible.
  • Female patients enrolled in the study, who are not free from menses for >2 years, post hysterectomy / oophorectomy, or surgically sterilized, must be willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from heterosexual activity throughout the study, starting with Visit 1 through 28 days after the last dose of study therapy. Approved contraceptive methods include for example; intra uterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, female condoms with spermicide, or oral contraceptives. Spermicides alone are not an acceptable method of contraception.

    -- Male patients must agree to use an adequate method of contraception starting with the first dose of study drug through 28 days after the last dose of study therapy.

  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Patient with a known history or evidence of brain metastases.
  • Patients who have had chemotherapy, radiation, hormonal, or biological cancer therapy within 28 days prior to the first dose of study drug excluding patients on long term hormonal therapies who have been on a stable dose for at least 3 months.
  • Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 28 days of the first dose of study drug.
  • Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc), celiac plexus block, and biliary stent placement.
  • Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study.
  • Patient who has had prior treatment with Mistletoe.
  • Patients who have received systemic corticosteroids within 28 days prior to the first dose of study drug. Note: Systemic steroid therapy is allowed for subjects on replacement therapy as long as prednisone ≤ 10 mg or its steroid equivalent.
  • Patients who have received systemic NSAID therapy within 14 days prior to the first dose of study drug.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Mistletoe.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Presence of ≥ CTCAE grade 2 toxicity (except peripheral neuropathy and ototoxicity, which are excluded if ≥ CTCAE grade 3) due to prior cancer therapy.
  • Autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); CNS or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and Myasthenia Gravis, multiple sclerosis). History of Grave's disease on stable thyroid hormone replacement for at least 1 year is allowed.
  • Patients with a known history of HIV, hepatitis B, hepatitis C, or tuberculosis infection. Patients with a history of cleared hepatitis C (undetectable viral loads) are allowed.
  • Women with a positive pregnancy test on enrollment or prior to investigational product administration
  • Women who are pregnant or breastfeeding.
  • Sexually active fertile men not using effective birth control if their partners are of child bearing potential.
  • Patient is unwilling or unable to comply with study procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03051477

Layout table for location information
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Believe Big
Layout table for investigator information
Principal Investigator: Channing Paller, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Layout table for additonal information
Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Identifier: NCT03051477    
Other Study ID Numbers: J1681
IRB00090991 ( Other Identifier: JHMIRB )
Helixor ( Other Identifier: Helixor Heilmittel GmbH & Co. KG. )
First Posted: February 13, 2017    Key Record Dates
Last Update Posted: February 24, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms